Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Merck & Co., Inc.
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First-Line Treatment for Patients With Unresectable or Metastatic Urothelial Carcinoma
July 26, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Announces Fourth-Quarter 2024 Dividend
July 23, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Announces Topline Results from Phase 2b/3 Trial of Clesrovimab (MK-1654), an Investigational Respiratory Syncytial Virus Preventative Monoclonal Antibody for Infants
July 23, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck to Share New Research and Host Community-Focused Symposia at AIDS 2024
July 16, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Completes Acquisition of EyeBio
July 12, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Animal Health Completes Acquisition of Elanco’s Aqua Business
July 09, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck and Orion Announce Mutual Exercise of Option Providing Merck Global Exclusive Rights to Opevesostat, an Investigational CYP11A1 Inhibitor, for the Treatment of Metastatic Castration-Resistant Prostate Cancer
July 01, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck to Hold Second-Quarter 2024 Sales and Earnings Conference Call July 30
July 01, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
CDC’S ACIP Unanimously Recommends Merck’s CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Appropriate Adults
June 27, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
USDA Approves Merck Animal Health’s NOBIVAC® NXT Canine Flu H3N2 – The First and Only RNA-Particle Technology Vaccine for Canine Influenza
June 25, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
U.S. FDA Approves CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults
June 17, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Carboplatin and Paclitaxel as Treatment for Adult Patients With Primary Advanced or Recurrent Endometrial Carcinoma
June 17, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
June 05, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment of Patients With Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma
May 29, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck to Acquire EyeBio
May 29, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Announces Third-Quarter 2024 Dividend
May 28, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Announces Phase 3 KEYNOTE-522 Trial Met its Overall Survival (OS) Endpoint in Patients With High-Risk Early-Stage Triple Negative Breast Cancer (TNBC)
May 28, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck to Present New Data at 2024 ASCO Annual Meeting Demonstrating Advancements in Novel Oncology Treatment Approaches Across Broad Portfolio and Diverse Pipeline
May 15, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Provides Update on Phase 3 KeyVibe-010 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab as Adjuvant Treatment for Patients With Resected High-Risk Melanoma
May 13, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Provides Update on Phase 3 KEYNOTE-B21 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Radiotherapy, for Patients With Newly Diagnosed, High-Risk Endometrial Cancer After Surgery With Curative Intent
May 09, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck to Participate in the Bank of America Securities 2024 Healthcare Conference
May 08, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival (OS) as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
May 01, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults
April 29, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Announces First-Quarter 2024 Financial Results
April 25, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer
April 04, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck to Hold First-Quarter 2024 Sales and Earnings Conference Call April 25
April 01, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for Resectable Non-Small Cell Lung Cancer (NSCLC) at High Risk of Recurrence in Adults
March 28, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
FDA Approves Merck’s WINREVAIR™ (sotatercept-csrk), a First-in-Class Treatment for Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1)
March 26, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Provides Update on Phase 3 KEYLYNK-006 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Maintenance LYNPARZA® (olaparib) for Certain Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer
March 21, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Announces Positive Data on V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Demonstrated Immune Responses in Adults
March 19, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.